5-Amino-1MQ vs SLU-PP-332

5-Amino-1MQ

A small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor, not a peptide. Evidence is preclinical: it reduced fat mass in diet-induced obese mice without changing food intake, and there are cell and rodent data on muscle stem cells. There are no published controlled human trials, so every dose figure here is extrapolated from vendor and community practice rather than clinical data — treat the range as low confidence. It is taken orally in capsules: 50-150 mg daily, with 100 mg typical, which in the microgram units used throughout this dataset is 50,000-150,000 mcg (100 mg = 100,000 mcg). It is swallowed as capsules rather than reconstituted, so the reconstitution fields do not apply.

SLU-PP-332

A synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), not a peptide. It is marketed as an "exercise mimetic" because in mice it increased oxidative metabolism, running endurance and fat oxidation and reduced fat gain on a high-fat diet without changing food intake. That is the entire evidence base: preclinical rodent and cell work from academic labs. There are NO human trials, no human pharmacokinetics, no human safety data and no published human dosing whatsoever — nothing here is derived from a study in people. It is sold as 1 mg oral tablets, so the 500-1000 mcg (0.5-1 mg) daily range shown is simply half a tablet to one tablet: a deliberately narrow, conservative reading of vendor packaging, not a validated dose. Human half-life is unknown, so it is left null rather than guessed. It is swallowed as tablets rather than reconstituted, so the reconstitution fields do not apply. Treat every number on this page as the lowest possible confidence.